Literature DB >> 22562721

Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?

Kjell Öberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22562721     DOI： 10.1007/s12020-012-9681-4

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  9 in total

1.  Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Jochen Schuhmacher; Uwe Haberkorn; Nikolaos Karkavitsas; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-17       Impact factor: 9.236

Review 2.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.

Authors:  Jean Claude Reubi; Beatrice Waser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-18       Impact factor: 9.236

3.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

Authors:  Jörg Kowalski; Marcus Henze; Jochen Schuhmacher; Helmut R Mäcke; Michael Hofmann; Uwe Haberkorn
Journal:  Mol Imaging Biol       Date:  2003 Jan-Feb       Impact factor: 3.488

Review 5.  Molecular theranostics: a primer for the imaging professional.

Authors:  Daniel Y Lee; King C P Li
Journal:  AJR Am J Roentgenol       Date:  2011-08       Impact factor: 3.959

Review 6.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.

Authors:  Giorgio Treglia; Paola Castaldi; Guido Rindi; Alessandro Giordano; Vittoria Rufini
Journal:  Endocrine       Date:  2012-02-20       Impact factor: 3.633

Review 7.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

8.  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Authors:  P Antunes; M Ginj; H Zhang; B Waser; R P Baum; J C Reubi; H Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-16       Impact factor: 10.057

Review 9.  Gastroenteropancreatic neuroendocrine tumours.

Authors:  Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316
  9 in total
  9 in total

1.  Cyclotron production of (68)Ga via the (68)Zn(p,n)(68)Ga reaction in aqueous solution.

Authors:  Mukesh K Pandey; John F Byrne; Huailei Jiang; Alan B Packard; Timothy R DeGrado
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

2.  Recurrent acute-onset Cushing's syndrome 6 years after removal of a thymic neuroendocrine carcinoma: from ectopic ACTH to CRH.

Authors:  Camilla Schalin-Jäntti; Sylvia L Asa; Johanna Arola; Timo Sane
Journal:  Endocr Pathol       Date:  2013-03       Impact factor: 3.943

Review 3.  Therapy for metastatic pancreatic neuroendocrine tumors.

Authors:  Roberta Elisa Rossi; Sara Massironi; Dario Conte; Maddalena Peracchi
Journal:  Ann Transl Med       Date:  2014-01

Review 4.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

5.  Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.

Authors:  Gianluca Tamagno; Kieran Sheahan; Stephen J Skehan; Justin G Geoghegan; David Fennelly; Conor D Collins; Donal Maguire; Oscar Traynor; David P Brophy; Colin Cantwell; Niall Swan; Lisa McGowan; Dermot O'Toole; Donal O'Shea
Journal:  Endocrine       Date:  2013-03-08       Impact factor: 3.633

Review 6.  Ectopic acromegaly due to growth hormone releasing hormone.

Authors:  Ali A Ghazi; Alireza Amirbaigloo; Azizollah Abbasi Dezfooli; Navid Saadat; Siavash Ghazi; Marina Pourafkari; Farrokh Tirgari; Dheepti Dhall; Serguei Bannykh; Shlomo Melmed; Odelia Cooper
Journal:  Endocrine       Date:  2012-09-15       Impact factor: 3.633

7.  Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2016-01-18

Review 8.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

Review 9.  Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.

Authors:  Irina Velikyan
Journal:  Contrast Media Mol Imaging       Date:  2018-01-04       Impact factor: 3.161
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.